Genetic landscape of pediatric acute myeloid leukemia in Taiwan

Read full text
Authors: Zhongshan Cheng, Sung‐Liang Yu, Chih-Hsiang Yu, Ti-Cheng Chang, Ya‐Hsuan Chang, Shiann‐Tarng Jou, Meng-Yao Lü, Kai-Hsin Lin, Chang Hsiu-Hao, Shu-Wei Chou, Ze‐Shiang Lin, C C Kuo
+10 more Phooi-Theng Liew, Chia-Jui Du, Chien‐Yu Lin, Yu-Ling Ni, Hsuan‐Yu Chen, Dong-Tsamn Lin, S C Lin, Gang Wu, Ching-Hon Pui, Yichen Yang
Cited by: 1
References: 82

Abstract

The international consensus classification or the World Health Organization classifications underrepresented driver alterations enriched in pediatric acute myeloid leukemia (AML). To address this, we retrospectively characterized the genomic landscape of 105 pediatric patients with AML of East Asian ancestry using transcriptome and whole-exome sequencing (WES). In addition to the common recurrent fusions such as RUNX1::RUNX1T1 and CBFB::MYH11, we identified rearrangements involving KMT2A, NUP98, GLIS, as well as FLT3 and UBTF tandem duplications. The median somatic mutation rate in AML was 0.97 per megabase, as estimated by WES. Frequently mutated pathways included signaling: 68.6% (72/105), transcription: 37.1% (39/105), epigenetic regulation: 26.7% (28/105), cohesin: 7.6% (8/105), RNA binding: 3.8% (4/105), and protein modification: 5.7% (6/105). When analyzed together, high-risk genetic subtypes including GLISr, UBTF tandem duplications, PICALM::MLLT10, and HOXr were significantly associated with poorer 5 year overall survival (OS) in multivariable analysis (p-value = 0.037). Although FLT3 internal tandem duplications were significantly associated with inferior 5 year OS in univariable analysis, this effect was not significant in multivariable analysis (p-value = 0.382). Patients with RUNX1 mutations had inferior 5 year OS in multivariable analysis (p-value = 0.009). These findings suggest specific genomic alterations that may refine risk stratification and guide future therapeutic protocols in Taiwanese pediatric patients with AML.

Fields of Study & Subjects

Acute Myeloid Leukemia Research Genomics and Rare Diseases Blood disorders and treatments

Publication details

Journal / source
Scientific Reports
Publisher
Springer Science and Business Media LLC
Volume
16
Issue
1
Pages
4024–4024
Publication date
7 January 2026
Language
EN